Alchemia Limited - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Alchemia Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Alchemia Limited - Product Pipeline Review - 2014', provides an overview of the Alchemia Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alchemia Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Alchemia Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Alchemia Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Alchemia Limited's pipeline products

Reasons to buy

- Evaluate Alchemia Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Alchemia Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Alchemia Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Alchemia Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alchemia Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Alchemia Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Alchemia Limited Snapshot 6
Alchemia Limited Overview 6
Key Information 6
Key Facts 6
Alchemia Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Alchemia Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Alchemia Limited - Pipeline Products Glance 12
Alchemia Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Alchemia Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Alchemia Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Alchemia Limited - Drug Profiles 17
irinotecan hydrochloride 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
doxorubicin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
fluorouracil 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Antibiotic Program 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
bevacizumab 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
carboplatin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
cetuximab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
fondaparinux sodium 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
gemcitabine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
methotrexate 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules to Inhibit Focal Adhesion Kinase for Solid Tumors 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
vinorelbine tartrate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule Targeting Parathyroid Hormone 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule Targeting Gastric Inhibitory Polypeptide 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule Targeting GLP-1 For Diabetes 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule Targeting Nav1.7 For Pain 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule Targeting Opioid Receptor For Pain 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule Targeting VPAC Receptor For COPD 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
VAST Based Drug For Multiple Indications 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Alchemia Limited - Pipeline Analysis 37
Alchemia Limited - Pipeline Products by Target 37
Alchemia Limited - Pipeline Products by Route of Administration 39
Alchemia Limited - Pipeline Products by Molecule Type 40
Alchemia Limited - Pipeline Products by Mechanism of Action 41
Alchemia Limited - Recent Pipeline Updates 43
Alchemia Limited - Discontinued Pipeline Products 46
Discontinued Pipeline Product Profiles 46
VAST Based Drug For Obesity 46
ACL-16907 46
Alchemia Limited - Company Statement 47
Alchemia Limited - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Alchemia Limited, Key Information 6
Alchemia Limited, Key Facts 6
Alchemia Limited - Pipeline by Indication, 2014 9
Alchemia Limited - Pipeline by Stage of Development, 2014 10
Alchemia Limited - Monotherapy Products in Pipeline, 2014 11
Alchemia Limited - Phase III, 2014 12
Alchemia Limited - Phase II, 2014 13
Alchemia Limited - Phase I, 2014 14
Alchemia Limited - Preclinical, 2014 15
Alchemia Limited - Discovery, 2014 16
Alchemia Limited - Pipeline by Target, 2014 38
Alchemia Limited - Pipeline by Route of Administration, 2014 39
Alchemia Limited - Pipeline by Molecule Type, 2014 40
Alchemia Limited - Pipeline Products by Mechanism of Action, 2014 42
Alchemia Limited - Recent Pipeline Updates, 2014 43
Alchemia Limited - Discontinued Pipeline Products, 2014 46
Alchemia Limited, Subsidiaries 49